RFCA
TEVA icon

R&F Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

R&F Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$1.12M Buy
34,954
+27,837
+391% +$950K 0.29% 83
2016
Q4 		$258K Buy
+7,117
New +$284K 0.09% 341

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

R&F Capital Advisors's TEVA Position: Q1 2017 in Review

R&F Capital Advisors increased its Teva Pharmaceuticals (TEVA) stake by 391% in Q1 2017, buying an estimated $950K and bringing the position to 34,954 shares worth $1.12M. The position accounts for 0.29% of the portfolio, ranked #83.

R&F Capital Advisors first reported a position in TEVA in Q4 2016 and has held it in 2 quarters since. 688 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • R&F Capital Advisors held 34,954 shares of Teva Pharmaceuticals worth $1.12M as of Q1 2017.
  • R&F Capital Advisors bought 27,837 Teva Pharmaceuticals shares in Q1 2017, an estimated $950K.
  • Teva Pharmaceuticals made up 0.29% of R&F Capital Advisors's portfolio in Q1 2017, its #83 holding.
  • R&F Capital Advisors first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 2 quarters since.
  • 688 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.